GH1 and diabetes mellitus: Limited clinical evidence in the setting of programming is available, as the use of GH in the clinic is restricted to those with tightly defined short stature and GHD, and there are potential safety concerns around the use of GH and subsequent diabetes/cancer risk [12,13].